Misplaced Pages

Detumomab: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

Browse history interactively ← Previous editContent deleted Content addedVisual WikitextInline

Revision as of 00:20, 20 February 2022 editFswitzer4 (talk \| contribs)Extended confirmed users10,572 editsm Added UNII← Previous edit		Latest revision as of 00:54, 14 May 2023 edit undoEntranced98 (talk \| contribs)Extended confirmed users, Pending changes reviewers, Rollbackers172,831 edits Adding local short description: "Monoclonal antibody", overriding Wikidata description "chemical compound"Tag: Shortdesc helper
Line 1:		Line 1:
			{{Short description\|Monoclonal antibody}}
	{{Drugbox		{{Drugbox
	\| Verifiedfields = changed		\| Verifiedfields = changed

Latest revision as of 00:54, 14 May 2023

Monoclonal antibody Pharmaceutical compound

Detumomab
Monoclonal antibody
Type	Whole antibody
Source	Mouse
Target	B-lymphoma cell
Clinical data
ATC code	none
Identifiers
CAS Number	145832-33-3
ChemSpider	none
UNII	8Z3Q8X4UAD
(what is this?) (verify)

Detumomab is a mouse monoclonal antibody targeting human B-cell lymphoma.

References

"International Nonproprietary Names (INN) for Pharmaceutical Substances" (PDF). WHO Drug Information. 7 (4). 1993. Archived from the original (PDF) on 14 June 2007.
Singh S, Kumar NK, Dwiwedi P, Charan J, Kaur R, Sidhu P, Chugh VK (2018). "Monoclonal Antibodies: A Review". Current Clinical Pharmacology. 13 (2): 85–99. doi:10.2174/1574884712666170809124728. PMID 28799485. S2CID 27211386.

v
t
e

Monoclonal antibodies for tumors

Human	Adecatumumab Amivantamab Ascrinvacumab Atezolizumab (+hyaluronidase) Balstilimab Botensilimab Cixutumumab Conatumumab Cosibelimab Daratumumab Drozitumab Duligotumab Dusigitumab Enfortumab vedotin Enoticumab Figitumumab Flanvotumab Ganitumab Glembatumumab vedotin Intetumumab Ipilimumab Iratumumab Istiratumab Icrucumab Lexatumumab Lucatumumab Mapatumumab Narnatumab Necitumumab Nesvacumab Nivolumab (+hyaluronidase, +relatlimab) Ofatumumab Olaratumab Panitumumab Patritumab Pembrolizumab Pritumumab Radretumab Ramucirumab Rilotumumab Robatumumab Seribantumab Sugemalimab Tarextumab Tisotumab vedotin Teprotumumab Tovetumab Vantictumab Votumumab Zalutumumab
Mouse	Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Nofetumomab merpentan Pintumomab Tenatumomab Tositumomab
Chimeric	Amatuximab Bavituximab Brentuximab vedotin Carotuximab Cetuximab Derlotuximab biotin Dinutuximab Ecromeximab Ensituximab Futuximab Girentuximab Indatuximab ravtansine Isatuximab Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab Siltuximab Ublituximab Zolbetuximab
Humanized	Abituzumab Alemtuzumab Axatilimab Belantamab mafodotin Bevacizumab Bivatuzumab mertansine Brontictuzumab Cantuzumab mertansine Cantuzumab ravtansine Cirmtuzumab Citatuzumab bogatox Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab Demcizumab Dalotuzumab Denintuzumab mafodotin Elotuzumab Emactuzumab Emibetuzumab Enoblituzumab Epcoritamab Etaracizumab Farletuzumab Ficlatuzumab Flotetuzumab Gemtuzumab ozogamicin Glofitamab Imgatuzumab Inotuzumab ozogamicin Labetuzumab Lifastuzumab vedotin Lintuzumab Lorvotuzumab mertansine Lumretuzumab Matuzumab Milatuzumab Naxitamab Nimotuzumab Obinutuzumab Ocaratuzumab Odronextamab Otlertuzumab Onartuzumab Oportuzumab monatox Parsatuzumab Pertuzumab Pinatuzumab vedotin Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine Sacituzumab govitecan Sibrotuzumab Simtuzumab Sofituzumab vedotin Tacatuzumab tetraxetan Tigatuzumab Trastuzumab (+deruxtecan / +emtansine) Tucotuzumab celmoleukin Vandortuzumab vedotin Vanucizumab Veltuzumab Vorsetuzumab mafodotin Zenocutuzumab
Rat/mouse hybrid	Catumaxomab Ertumaxomab
Chimeric + humanized	Depatuxizumab mafodotin Duvortuxizumab Ontuxizumab

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

v
t
e

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

v
t
e